Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Section Navigation
			
			CDC Home


Facebook
        Twitter
        LinkedIn
        Syndicate





Tuberculosis Epidemiologic Studies Consortium (TBESC)										Related Pages
										**TBESC-II**
		On This Page
			TBESC-IIStudy 1: Evaluating tests for TB infectionStudy 2: The latent TB infection care cascadeStudy 3:  Closing the gaps in the TB care cascadeTBESC-I
		
**Study Sites**
California Department of Public Health
Denver Health and Hospital Authority, Colorado
Duke University, North Carolina and Tennessee
Emory University, Georgia
Hawaii Department of Health
Public Health-Seattle and King County, Washington
Maricopa County Department of Public Health, Arizona
Maryland Department of Health and Mental Hygiene
University of Florida
University of North Texas Health Science Center**Study 1: Evaluating tests for TB infection**
This first TBESC-II study was a head-to-head comparison of the three tests for TB infection in populations at high risk of latent TB infection and/or progression to TB disease.
**Sub studies**
Repeatability and reproducibility of two interferon-gamma release assay (IGRA) blood tests– the QuantiFERON®-TB Gold In-Tube (QFT-GIT), and T-SPOT®.*TB* test (T-SPOT)
Feasibility and cost of testing for prediabetes and diabetes in high-risk persons tested for TB infection
Cost-effectiveness of TB infection testing in high-risk populations**Study 2: The latent TB infection care cascade**
The second study focused on describing and quantifying the steps in the TB prevention cascade of care within health department clinics. This included better understanding the proportions of patients with latent TB infection who are identified, offered treatment, accept treatment, and complete treatment.
**Sub studies**
Developed algorithms to estimate latent TB infection prevalence at any county or state level.
Developed tools for local TB programs to identify local clinicians who treat underserved populations at high risk, so they can partner with these groups to increase latent TB infection treatment.
Used insurance billing codes to estimate the extent and magnitude of latent TB infection testing and treatment in commercial and community health sectors.**Study 3:  Closing the gaps in the TB care cascade**
The third study focused on identifying barriers and facilitators to latent TB infection diagnosis and treatment at community health clinics (CHCs). Researchers collected and analyzed quantitative and qualitative data that can be used to inform development of interventions to improve targeted TB testing and latent TB infection treatment at CHCs.**TBESC-I**
Research Projects information
Tuberculosis Epidemiologic Studies Consortium Research ProjectsTask Order
Task Order Title
Principal Investigator32
The Current Cost of TB within urban United States
Jenny Pang
Thad Miller
Dolly Katz31
Evaluation of Interferon Gamma Release Assays in Overseas Immigration Examination of Children in Moderate- and High-burden Countries
Denise Garrett
John Painter
Drew Posey
Domestic:
Randall Reves30
Quantifying the risk of premature death in TB survivors
Suzanne Beavers
Thad Miller
Jenny Pang29**
Improving testing for TB and latent TB infection for Persons with HIV Infection at HRSA-funded HIV/AIDS Clinics
Suzanne Marks28
Treatment Practices, Outcomes and Cost of Multidrug-resistant (MDR TB) and Extensively Drug Resistant Tuberculosis (XDR TB) in the United States
Suzanne Marks
Lori Armstrong27
Use of Nucleic Acid Amplification Test to Determine the Relative Infectiousness of Pulmonary TB Patients
Suzanne Marks26
Improving the Utilization and Integration of TB Genotyping into Routine TB Program Practice: Analyzing the Impact Through Public Health Interventions
Roque Miramontes
Wendy Cronin25
Tuberculosis Mortality in the United States: Epidemiology and Prevention Opportunities
Suzanne Beavers
Jenny Flood24
Perceptions of TB among the Karen-Burmese: An Ethnographic Study
Robin Shrestha-Kuwahara23
National Study of Determinants of Early Diagnosis, Prevention, and Treatment of TB in the African-American Community
Rachel Royce
Dolly Katz21
Acquired Rifamycin-resistant TB among HIV infected patients
Sundari Mase20
Assessing QFT as an initial screening tool for U.S. bound applicants for immigration and feasibility of follow-up in U.S. immigrants
Randall Reves
John Painter
Lilia Manangan19
Effectiveness of Quantiferon- TB Gold (QFT-G) in contact tracing
Lauren Lambert
Sharon Welbel18
Evaluation of New Interferon-y Release Assays in the Diagnosis of Latent TB Infection in Health Care Workers
Denise Garrett
Charles Daley
Susan Dorman16*
African Refugee Women’s Health Improvement Project
Sue Etkind
Jennifer Cochran15
Enhancing TB Programs’ Capacity for Self-Evaluation: Testing New Tools and Developing an Evaluation Toolkit
Maureen Wilce14
Culturally Appropriate TB Educational Materials for Leaders and Staff of Hispanic Service Organizations
Wanda Walton13
Factors Associated with Acceptance of, Adherence to and Toxicity From Treatment for Latent TB Infection and Pilot Study of Treatment for Latent TB Infection Effectiveness
Robin Shrestha-Kuwahara
Stefan Goldberg
Paul Colson,
Yael Hirsch-Moverman12
Assessing the TB Knowledge, Attitudes, Beliefs, and Practices Among Private Providers Serving Foreign-born Populations at Risk for TB
Wanda Walton
Jenny Pang11
Addressing TB Among African Americans in the Southeast: Identifying and Overcoming Barriers to Treatment Adherence for Latent TB Infection and TB Disease
Wanda Walton
Rachel Royce10
New Model for Assessing TB Surveillance and Action Performance and Cost
Scott McNabb9
Missed Opportunities for TB Prevention in Foreign-Born Population in the United States and Canada
Dolly Katz
Randall Reves
Amy Davidow8
An Analysis of Molecular Epidemiology of Multi-Drug Resistant M. tuberculosis in the United States
Edward Graviss
Patrick Moonan
Jenny Flood7
Use of Network Analysis Methods to Characterize M. tuberculosis Transmission Patterns Among Women and Other High-Risk Populations
Peter McElroy
Maureen Wilce6
Regional Capacity-Building in Low-Incidence Areas
Paul Tribble5
Prevalence of Latent TB Infection Among High Risk Populations in the United States
Rachel Albalak4
Models for Incorporating HIV Counseling, Testing, and Referral into Tuberculosis Contact Investigations
Suzanne Marks3
Zero Tolerance for Pediatric TB
Mark Lobato2
Prospective Evaluation of Immunogenetic and Immunologic Markers for Susceptibility to Tuberculosis Infection and Progression from M. Tuberculosis infection to active TB
Mary Reichler
Tim Sterling1
TBES Consortium: Core Requirements*Alternate Track Task Order: Local initiative not reviewed and monitored by Research Committee
**Outside Funding Task Order: Project funded from outside of CDC Division of TB Elimination. Reviewed and monitored by Research Committee
							
					
						Page last reviewed:  August 1, 2012					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue